Showing results (161-170 of 202) with videos related to

Sort By:
Pageof 21
Bone Marrow Transplantation|April 22, 2026
Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)Fabio Andreozzi, Jacques-Emmanuel Galimard, Johan Maertens, et al.
Transplantation and Cellular Therapy|June 16, 2026
Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine OutcomeAnnemarie Mohring, Katja Sockel, Christian Thiede, et al.
Bone Marrow Transplantation|March 24, 2025
Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMTNicole Santoro, Christoph Schmid, Moniek de Witte, et al.
Bone Marrow Transplantation|July 7, 2023
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)Eleni Gavriilaki, Ioanna Sakellari, Myriam Labopin, et al.
Bone Marrow Transplantation|June 4, 2024
Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working partyJean El Cheikh, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|July 2, 2026
A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemiaAlexandros Spyridonidis, Allain Thibeault Ferhat, Jacques Emmanuel Galimard, et al.
The Lancet. Oncology|June 1, 2026
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialTheodore L DeWeese, Andrea Manzanera, John Sylvester, et al.
Hemasphere|January 26, 2023
Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMTAlexandros Spyridonidis, Myriam Labopin, Bipin Savani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2022
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT AnalysisArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Pageof 21